Zerion Pharma is a Academic/Research company operating in the pharmaceutical industry.
Zerion Pharma A/S is a pharmaceutical company aspiring to transform the pharmaceutical landscape for the formulation of poorly soluble drugs that are currently not reaching their therapeutic potential. The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion Pharma A/S has pioneered the Dispersome(R) technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and therapeutic options for patients. The Dispersome(R) technology is based around a class of novel excipient, namely beta-lactoglobulin (BLG), to formulate poorly soluble small molecule drugs into stable amorphous drug delivery systems with a high drug load. By increasing solubility and dissolution rate the Dispersome(R) platform aims at improving bioavailability and therapeutic outcomes and reducing adverse effects in patients. The Dispersome(R) technology is well accepted with no safety risks and compatible with standard solid oral dosage form manufacturing.
Company type
Academic/Research
Products and services
Excipients, Finished Dosage Forms, Contract Services – Analytical & Lab Services, Pharmaceutical Machinery & Technology
Markets
North America (USA, Canada), Europe – EU countries
Useful Links
Connect with Zerion Pharma on LinkedIn
Address
Zerion Pharma, Fruebjergvej 3, Copenhagen, Denmark, DK2100
Stay ahead of trends and best practices
